← All drugs
Drug · FAERS side-effect profile with label screen

Oxycodone and Acetaminophen Tablets side effects: what 11,842 FDA adverse event reports show

Oxycodone And Acetaminophen Tablets · 1,094 reaction terms · 95,527 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Label matched

Oxycodone (Oxycodone Hydrochloride)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

11,842 reports · 70% serious · 1,570 with death outcome · 63% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.

FDA label, Indications and Usage

What it is

Oxycodone HCl tablets, USP contains oxycodone, an opioid agonist.

FDA label, Description section

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 2Labeled (related wording) 5Lab value / disease marker 7Not in label — unassessed 26
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,054 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vision abnormal neonatal71357.1
276.8–460.7ROR 359.2 · calibrated p 4e-12 ✓
274.7 EB05 225.1 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=71 · 100% consumerno trial arm names this drug
Grip strength38347.2
245.2–491.6ROR 348.3 · calibrated p 9e-12 ✓
253.0 EB05 192.4 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=38 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Swollen joint count29236.5
160.5–348.4ROR 237.1 · calibrated p 4e-10 ✓
183.4 EB05 133.9 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=29 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Neonatal hypoacusis26220.3
146.5–331.1ROR 220.8 · calibrated p 8e-10 ✓
171.3 EB05 122.8 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=26 · ♀ 38% (drug 63%) · 100% consumerno trial arm names this drug
Sleep disorder due to general medical condition, hypersomnia type10196.1
102.0–376.9ROR 196.3 · calibrated p 1e-8 ✓
132.5 EB05 76.9 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=10no trial arm names this drug
Deep vein thrombosis postoperative184183.3
157.6–213.1ROR 186.2 · calibrated p 9e-10 ✓
163.2 EB05 144.3 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 100% (drug 63%) · 96% clinicianno trial arm names this drug
Lupus vulgaris100162.3
132.4–199.1ROR 163.7 · calibrated p 3e-9 ✓
144.6 EB05 122.3 · IC025 +6.1
3/3 methods agree
Not in label — unassessedserious n=100 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Duodenal ulcer perforation539140.3
128.7–152.8ROR 146.9 · calibrated p 6e-9 ✓
129.3 EB05 120.4 · IC025 +6.7
3/3 methods agree
Not in label — unassessedserious PRR 107.2 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody49140.2
104.8–187.4ROR 140.8 · calibrated p 2e-8 ✓
123.7 EB05 97.3 · IC025 +5.3
3/3 methods agree
Lab value / disease markerserious n=49 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
X-ray abnormal130139.0
116.4–166.1ROR 140.5 · calibrated p 1e-8 ✓
126.5 EB05 109.3 · IC025 +6.1
3/3 methods agree
Lab value / disease markerserious n=130 · ♀ 100% (drug 63%) · 95% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive517138.9
127.2–151.6ROR 145.1 · calibrated p 6e-9 ✓
128.1 EB05 119.1 · IC025 +6.7
3/3 methods agree
Lab value / disease markerserious PRR 106.7 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Adjustment disorder with depressed mood145137.2
115.9–162.3ROR 138.8 · calibrated p 1e-8 ✓
125.2 EB05 109.0 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=145 · ♀ 100% (drug 63%) · 96% clinicianno trial arm names this drug
C-reactive protein63132.0
102.2–170.4ROR 132.7 · calibrated p 2e-8 ✓
118.5 EB05 95.9 · IC025 +5.6
3/3 methods agree
Lab value / disease markerserious n=63 · ♀ 100% (drug 63%) · 95% clinicianno trial arm names this drug
Swollen joint count increased200121.2
105.2–139.8ROR 123.3 · calibrated p 3e-8 ✓
112.2 EB05 99.8 · IC025 +6.2
3/3 methods agree
Lab value / disease markerserious n=200 · ♀ 100% (drug 63%) · 96% clinicianno trial arm names this drug
Learning disability339118.7
106.5–132.3ROR 122.1 · calibrated p 3e-8 ✓
110.5 EB05 101.0 · IC025 +6.4
3/3 methods agree
Not in label — unassessedserious n=339 · ♀ 40% (drug 63%) · 100% consumerno trial arm names this drug
Dislocation of vertebra137116.1
97.8–137.9ROR 117.5 · calibrated p 4e-8 ✓
107.3 EB05 93.1 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious n=137 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Folliculitis634115.7
107.0–125.2ROR 122.2 · calibrated p 2e-8 ✓
108.2 EB05 101.4 · IC025 +6.5
3/3 methods agree
Not in label — unassessedserious PRR 105.5 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Porphyria acute77104.5
83.1–131.4ROR 105.2 · calibrated p 1e-7 ✓
96.4 EB05 79.6 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=77 · ♀ 100% (drug 63%) · 92% clinicianno trial arm names this drug
Helicobacter infection553101.5
93.3–110.4ROR 106.4 · calibrated p 7e-8 ✓
95.7 EB05 89.2 · IC025 +6.3
3/3 methods agree
Not in label — unassessedserious PRR 83.7 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Facet joint syndrome16295.8
81.9–112.1ROR 97.2 · calibrated p 2e-7 ✓
90.0 EB05 78.9 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious n=162 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Rheumatic fever21792.5
80.8–105.9ROR 94.2 · calibrated p 2e-7 ✓
87.2 EB05 77.9 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious n=217 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Retinitis7684.4
67.1–106.1ROR 84.9 · calibrated p 5e-7 ✓
79.0 EB05 65.2 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=76 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Pemphigus55983.3
76.7–90.5ROR 87.4 · calibrated p 3e-7 ✓
79.3 EB05 74.0 · IC025 +6.1
3/3 methods agree
Not in label — unassessedserious PRR 66.0 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Hand deformity56179.3
73.0–86.1ROR 83.2 · calibrated p 5e-7 ✓
75.7 EB05 70.6 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious PRR 68.2 · ♀ 99% (drug 63%) · 93% clinicianno trial arm names this drug
Rheumatoid factor positive22170.5
61.7–80.5ROR 71.8 · calibrated p 1e-6 ✓
67.4 EB05 60.3 · IC025 +5.7
3/3 methods agree
Lab value / disease markerserious n=221 · ♀ 100% (drug 63%) · 95% clinicianno trial arm names this drug
Developmental delay34669.9
62.9–77.8ROR 72.0 · calibrated p 1e-6 ✓
67.0 EB05 61.3 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious PRR 56.4 · ♀ 42% (drug 63%) · 100% consumerno trial arm names this drug
Presbyacusis1164.9
35.5–118.4ROR 64.9 · calibrated p 1e-5 ✓
56.7 EB05 33.8 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=11no trial arm names this drug
Pericarditis55260.6
55.8–65.8ROR 63.5 · calibrated p 3e-6 ✓
58.5 EB05 54.5 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious PRR 48.8 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Irritable bowel syndrome63554.2
50.2–58.5ROR 57.2 · calibrated p 6e-6 ✓
52.5 EB05 49.2 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious PRR 54.9 · ♀ 99% (drug 63%) · 92% clinicianno trial arm names this drug
Synovitis53353.8
49.5–58.6ROR 56.3 · calibrated p 6e-6 ✓
52.2 EB05 48.5 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious PRR 45.2 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Substance use disorder8349.1
39.5–61.0ROR 49.4 · calibrated p 2e-5 ✓
47.3 EB05 39.3 · IC025 +4.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=82 · 100% consumerno trial arm names this drug
C-reactive protein abnormal16145.6
39.0–53.3ROR 46.2 · calibrated p 2e-5 ✓
44.2 EB05 38.8 · IC025 +5.0
3/3 methods agree
Lab value / disease markerserious n=161 · ♀ 100% (drug 63%) · 92% clinicianno trial arm names this drug
Bone erosion8845.1
36.5–55.6ROR 45.4 · calibrated p 3e-5 ✓
43.6 EB05 36.4 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=88 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Drug withdrawal syndrome neonatal36944.7
40.4–49.5ROR 46.1 · calibrated p 2e-5 ✓
43.6 EB05 40.0 · IC025 +5.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 36.2 · ♀ 43% (drug 63%) · 100% consumerno trial arm names this drug
Autoimmune disorder19336.4
31.6–41.9ROR 37.0 · calibrated p 9e-5 ✓
35.6 EB05 31.5 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious PRR 31.6 · ♀ 98% (drug 63%) · 94% clinicianno trial arm names this drug

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Oxycodone and Acetaminophen Tablets only as a background or rescue medication (NCT02625181, NCT04296396); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Pain1,4814.3
4.1–4.5ROR 4.7 · calibrated p 0.266
4.3 EB05 4.1 · IC025 +2.0
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 4.7no trial arm names this drug
Fatigue (tiredness)1,4373.3
3.1–3.4ROR 3.6 · calibrated p 0.463
3.3 EB05 3.1 · IC025 +1.6
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 4.0no trial arm names this drug
Drug ineffective (drug did not work)1,4171.9
1.8–2.0ROR 2.0 · calibrated p 0.960
1.9 EB05 1.8 · IC025 +0.8Reporting / coding artifactserious PRR 2.6no trial arm names this drug
Dyspnoea (shortness of breath)1,0583.3
3.1–3.5ROR 3.5 · calibrated p 0.475
3.3 EB05 3.1 · IC025 +1.6
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 3.4 · ♀ 84% (drug 63%)no trial arm names this drug
Nausea9852.2
2.1–2.3ROR 2.3 · calibrated p 0.893
2.2 EB05 2.1 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 2.3no trial arm names this drug
Arthralgia (joint pain)9684.1
3.9–4.4ROR 4.4 · calibrated p 0.308
4.1 EB05 3.9 · IC025 +1.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 5.4 · ♀ 88% (drug 63%)no trial arm names this drug
Headache9022.6
2.4–2.7ROR 2.7 · calibrated p 0.740
2.5 EB05 2.4 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 3.2 · ♀ 85% (drug 63%)no trial arm names this drug
Rash8723.6
3.3–3.8ROR 3.8 · calibrated p 0.424
3.6 EB05 3.4 · IC025 +1.7
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 5.9 · ♀ 90% (drug 63%)no trial arm names this drug
Pruritus (itching)8564.0
3.8–4.3ROR 4.2 · calibrated p 0.335
4.0 EB05 3.8 · IC025 +1.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 7.1 · ♀ 93% (drug 63%)no trial arm names this drug
Peripheral swelling8239.5
8.9–10.2ROR 10.2 · calibrated p 0.031 ✓
9.5 EB05 8.9 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious PRR 12.7 · ♀ 92% (drug 63%)no trial arm names this drug
Pyrexia (fever)8214.2
3.9–4.5ROR 4.4 · calibrated p 0.305
4.2 EB05 4.0 · IC025 +2.0
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 4.2 · ♀ 91% (drug 63%)no trial arm names this drug
Diarrhoea (diarrhea)8062.2
2.1–2.4ROR 2.3 · calibrated p 0.899
2.2 EB05 2.1 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 2.4no trial arm names this drug
Nasopharyngitis (common cold)7937.6
7.1–8.2ROR 8.1 · calibrated p 0.064
7.6 EB05 7.1 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious PRR 13.0 · ♀ 95% (drug 63%)no trial arm names this drug
Infection7909.7
9.1–10.4ROR 10.4 · calibrated p 0.029 ✓
9.7 EB05 9.1 · IC025 +3.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 9.8 · ♀ 95% (drug 63%)no trial arm names this drug
Joint swelling77011.4
10.6–12.2ROR 12.1 · calibrated p 0.016 ✓
11.3 EB05 10.6 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 15.6 · ♀ 96% (drug 63%)no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Oxycodone and Acetaminophen Tablets?

In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone and Acetaminophen Tablets are pain, fatigue, dyspnoea, nausea, arthralgia, headache. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Oxycodone and Acetaminophen Tablets have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

Do FAERS signals prove that Oxycodone and Acetaminophen Tablets causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.